Trial Profile
An Open-label, Randomized, Phase 3 Study of Nivolumab, Nivolumab combined with Ipilimumab, or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jun 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2016 Planned End Date changed from 1 Oct 2016 to 31 Jul 2016.
- 03 Feb 2016 New trial record